Publication: Duchenne muscular dystrophy management and treatment access challenges: Case report
Published in the New Emirates Medical Journal, this case report discusses the challenges of treatment access and meeting Duchenne muscular dystrophy (DMD) care guidelines in the Middle East in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Learn about the challenges of caring for patients with nmDMD in the Middle East
Explore the effectiveness of the first use of ataluren in patients with nmDMD in this region
Understand the impact of timely diagnosis and management in patients with nmDMD
El-Azzabi TI. New Emir Med J. 2023;4(1)
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Once registered, you will be able to view the abstract and be provided the DOI link for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300173 | January 2024
Sign in or register to access exclusive content on this site